Compare Globus Medical Inc. Class A Common Stock (GMED) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while State Street SPDR S&P Biotech ETF trades at $147.16 (market cap $10.05B). The key difference: Globus Medical Inc. Class A Common Stock and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| GMED | XBI | |
|---|---|---|
Market Cap | $10.25B | $10.05B |
Volume | 1,059,528 | 10,367,649 |
Sector | Health | Broad Market / Factor |
52-Week High | $96.82 | $169.55 |
52-Week Low | $58.33 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
XBI trades at $146.8, down 3.04% today amid a bearish technical signal. The ETF's modified equal-weight structure provides exposure to over 150 biotech names, benefiting from M&A activity and positive clinical catalysts. Recent news highlights a 76% prior-year rally and optimism around cancer vaccine breakthroughs from Merck and Moderna. However, the ETF carries higher volatility and expense ratios compared to broader healthcare funds.
Outlook remains mixed with technical indicators bearish but fundamental catalysts present. Investment opportunity lies in targeted biotech exposure and sector innovation, though risks include high volatility, regulatory uncertainty, and reliance on clinical trial successes. Analyst consensus is neutral with 100% hold rating, suggesting cautious optimism amid recent price declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
